A Mab A Case Study In Bioprocess Development Jun 2026

This article presents a detailed case study of the development process for a humanized monoclonal antibody ("mAb A" or "the mAb"), focusing on the transition from early clone selection to the optimization of upstream cultivation and downstream purification strategies, emphasizing a Quality by Design (QbD) approach. 1. Project Background: Defining the Monoclonal Antibody

This case study demonstrates that a well-developed manufacturing process is crucial for transitioning a mAb from a research project to a successful, life-saving therapeutic.

Mab-X requires two polishing steps due to a closely related charge variant (a deamidated isoform at Asn-55). A Mab A Case Study In Bioprocess Development

The , published by the CMC Biotech Working Group , is a foundational document in the biopharmaceutical industry. It serves as a mock regulatory submission to demonstrate how Quality by Design (QbD) principles from ICH guidelines (Q8, Q9, and Q10) can be applied to the development of a monoclonal antibody . 1. Identify Quality Attributes

The A-mAb case study highlights that QbD is not merely a documentation exercise but a strategic approach to development. This article presents a detailed case study of

The N-glycan profiling via hydrophilic interaction liquid chromatography (HILIC) confirmed that the structural integrity of the fragment crystallizable (Fc) region was maintained. This ensured optimal antibody-dependent cellular cytotoxicity (ADCC) effector function. 5. Summary of Results and Key Takeaways

However, this initial process had limitations: Mab-X requires two polishing steps due to a

One critical insight: Routine HCP ELISA does not detect a specific CHO protein (Cathepsin D) that co-elutes with Mab-X during AEX. The team adds a secondary orthogonal method (LC-MS/MS) to verify HCP clearance.

To demonstrate the application of QbD in bridging bioprocess development with regulatory expectations.

Methotrexate (MTX) amplification was used to select high-producing clones.

While perfusion culture offers high density, a was selected for mAb-101 due to its operational simplicity, lower risk of mechanical failure, and easier tech transfer to existing manufacturing facilities. Seed Expansion (N-1) Production Bioreactor (N) Temperature 36.5°C (Shift to 33.0°C on Day 5) pH Control 7.00 ± 0.05 6.90 ± 0.10 Dissolved Oxygen (DO) Feeding Strategy None (Batch) Bolus feed (Days 3, 5, 7, 9, 11)